Jiashitang: Announcement of Resolutions of the 21st Meeting of the Seventh Board of Directors
Securities code: 002462 Securities abbreviation: Jiashitang Announcement number: 2026-06
Jiashitang Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 21st Meeting of the Seventh Board of Directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Convening of board of directors meetings
The 21st meeting of the seventh board of directors of Jiashitang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" and "the Company") was notified of the meeting by email on February 28, 2026. The meeting will be held by on-site voting at 14:00 on March 13, 2026. There were 9 directors who were supposed to vote at the meeting and 9 directors who actually voted. The meeting is chaired by the chairman. The convening and voting procedures of this meeting complied with the relevant provisions of the Company Law, the Articles of Association and the Rules of Procedure of the Board of Directors.
2. Review status of board of directors meeting
- Proposal on the 2025 Annual Work Report of the Board of Directors
With 9 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
2025 is the final year of the "14th Five-Year Plan" and the year of planning for the "15th Five-Year Plan". The board of directors of Jiashitang strictly abides by laws, regulations and the company's articles of association, abides by its fiduciary responsibilities, fully implements the resolutions of the shareholders' meeting through a sound scientific decision-making mechanism and dynamic supervision system, and continues to improve the corporate governance structure. All directors uphold the professional code of diligence and responsibility, perform their governance responsibilities with professionalism, conscientiously perform their duties assigned by shareholders, and effectively safeguard the legitimate rights and interests of the company and its shareholders.
The report must be reviewed by the shareholders' meeting.
The company's independent directors, Mr. Liang Yu, Mr. Xiong Yan, and Ms. Zhang Haiyan, submitted the "Independent Directors' Work Report" to the board of directors and will resign at the 2025 annual shareholders' meeting. For details of the "Independent Directors' Work Report", please see the cninfo website (http://www.cninfo.com.cn) on March 14, 2026.
- Proposal on the summary of business work in 2025
With 9 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
In 2025, under the strong leadership of the Group Party Committee and the Company Party Committee, Jiashitang faced a severe and complex situation. The management team, together with all employees, closely focused on the main line of the "Year of Compliance Construction" and adopted the strategy of "stabilizing stock, seizing growth, and strengthening reserves" to stabilize operations, strengthen rectification, and promote reform. It has consolidated its foundation in the face of adversity and won space for transformation and adjustment.
- Proposal on the 2025 internal control self-evaluation report
With 9 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
The company prepared the "2025 Internal Control Self-Evaluation Report" to explain the internal control situation in 2025; Lixin Accounting Firm (Special General Partnership) issued the "Jiashitang Pharmaceutical Co., Ltd. Internal Control Audit Report".
For details of the "2025 Internal Control Self-Evaluation Report" and "Jiashitang Pharmaceutical Co., Ltd. Internal Control Audit Report", please see the cninfo.com (http://www.cninfo.com.cn) on March 14, 2026. The proposal has been reviewed and approved by the company's audit committee.
- Proposal on the self-examination form for the implementation of internal control rules in 2025
With 9 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
The proposal has been reviewed and approved by the company's audit committee.
- Proposal on the 2025 Financial Final Account Report
With 9 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
In 2025, the company's consolidated revenue was 19,525,150,161.97 yuan, the company's consolidated net profit was 101,710,503.78 yuan, and the company's consolidated statement net profit attributable to the owners of the parent company was 111,378,719.41 yuan. The parent company achieved a net profit of 235,860,792.15 yuan. Adding the undistributed profit of 1,923,851,369.80 yuan at the beginning of the year and subtracting the 2024 shareholder dividend amount of 49,590,210.40 yuan, the parent company's profit available for distribution to shareholders is 2,110,121,951.55 yuan.
The proposal has been reviewed and approved by the company's audit committee. The report must be reviewed by the shareholders' meeting.
- Proposal on the profit distribution plan for 2025
With 9 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
For details of the "Profit Distribution Plan for 2025", please see the cninfo.com (http://www.cninfo.com.cn) on March 14, 2026.
The plan must be reviewed by the shareholders' meeting.
- Proposal on the 2025 Annual Report and its Summary
With 9 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
For details of the "Full Text of the Company's 2025 Annual Report", please see the Juchao Information Network (http://www.cninfo.com.cn) on March 14, 2026; for "Summary of the 2025 Annual Report", see "Securities Daily", "Securities Times" and the Juchao Information Network (http://www.cninfo.com.cn) on March 14, 2026. The report must be reviewed and approved by the shareholders' meeting.
- Proposal on the expected daily related transactions in 2026
Ms. Pan Wei, the relevant director of this proposal, abstained from voting.
With 8 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
For details of the "Estimated Daily Related Transactions in 2026", please see the cninfo website (http://www.cninfo.com.cn) on March 14, 2026.
This proposal was reviewed and approved by the company’s first special meeting of independent directors in 2026. The proposal must be reviewed and approved by the shareholders' meeting, and related shareholders shall abstain from voting.
- Proposal on the 2025 Social Responsibility Report
With 9 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
For details of the "2025 Social Responsibility Report", please see the cninfo website (http://www.cninfo.com.cn) on March 14, 2026.
- Proposal on Provision for Goodwill Impairment in 2025
With 9 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
For details of the "Announcement on Provision for Goodwill Impairment", please refer to the cninfo website (http://www.cninfo.com.cn) on March 14, 2026.
- Proposal on applying to the bank for a comprehensive credit line in 2026
Ms. Pan Wei, the relevant director of this proposal, abstained from voting.
With 8 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
For details of the "Announcement on Applying to Banks for Comprehensive Credit Lines in 2026", please see the cninfo.com (http://www.cninfo.com.cn) on March 14, 2026.
The proposal must be reviewed and approved by the shareholders' meeting, and related shareholders shall abstain from voting.
- Regarding the proposal to provide guarantees for subsidiaries to apply for bank credit in 2026, 9 votes were in favor, 0 votes were against, and 0 abstentions were cast. The motion was passed.
"Announcement on Providing Guarantees for Subsidiaries' Application for Bank Credit in 2026" can be found on the cninfo.com (http://www.cninfo.com.cn) on March 14, 2026.
- Proposal on correcting accounting errors in previous periods
With 9 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
Please refer to the "Announcement on the Correction and Retroactive Adjustment of Accounting Errors in the Previous Period" on March 14, 2026 on the cninfo website (http://www.cninfo.com.cn).
The proposal has been reviewed and approved by the company's audit committee.
- Proposal on convening the 2025 annual shareholders’ meeting
With 9 votes in favor, 0 votes against, and 0 abstentions, the motion was passed.
After deliberation, the board of directors believes that the company’s convening of the 2025 annual shareholders’ meeting complies with laws, administrative regulations and the provisions of the China Securities Regulatory Commission.
The company plans to hold the company's 2025 annual shareholders' meeting on June 29, 2026 (Monday). For details of the meeting notice and announcement, please see Securities Daily, Securities Times and Juchao Information Network (http://www.cninfo.com.cn) on March 14, 2026.
3. Documents for reference
Resolution of the 21st meeting of the seventh board of directors;
Resolution of the first special meeting of independent directors in 2026;
Resolution of the first meeting of the Audit Committee of the seventh board of directors in 2026.
Board of Directors of Jiashitang Pharmaceutical Co., Ltd.
March 14, 2026